Comparison of Effect & Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to demonstrate that the combination therapy of aspirin and
clopidogrel napadisilate is not inferior to that of aspirin and clopidogrel bisulfate with
respect to its effectiveness in inhibiting platelet aggregation, if it is given for four
weeks to Coronary Artery Disease (CAD) patients who had been treated with a drug-eluting
stent before > 12 months and had remained in a stable condition with a single antiplatelet
agent, aspirin.